Hologic signed an agreement this week to acquire the medical aesthetics company Cynosure for approximately $1.65 billion. It will purchase all of Cynosure's outstanding shares for $66 each in cash.
Cynosure has a portfolio of over 20 products for noninvasive body contouring, hair removal, skin revitalization and women's health. The products are sold through direct sales and distributors in 130 plus countries.
The company recently launched the world's first FDA-cleared laser treatment for noninvasive body contouring, SculpSure. It also owns a carbon-dioxide laser for women's health called MonaLisa Touch.
Cynosure raked in $433.5 million in 2016 and reported top-line growth in 28 consecutive quarters. About 60 percent of the company's business comes from physicians outside the traditional areas of plastic surgery and dermatology, with a significant focus on OB/GYN applications.
The global medical aesthetics segment is worth more than $2 billion and is expected to grow at a low double-digit rate over the next few years. The aging population is taking an interest in aesthetics and physicians are looking to increase their cash-based procedures.
The aesthetics segment is not "subject to reimbursement risks, making it less cyclical," Margaret Kaczor, analyst at William Blair, told Reuters.
"Larger acquirers can access a fast growing, profitable market that is just in the first quarter of the game," she added.
On Monday, Botox manufacturer Allergan purchased Cynosure's competitor Zeltiq Aesthetics for around $2.48 billion.
The Hologic-Cynosure deal has an enterprise value of $1.44 billion net of cash. Hologic expects realized annualized cost synergies of about $25 million, three years after the close of the deal.